Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endeavor IV stent data

This article was originally published in The Gray Sheet

Executive Summary

In the lead up to an Oct. 10 PMA panel review, FDA has released detailed results from Medtronic's Endeavor IV trial showing its Endeavor zotarolimus-eluting stent to be as effective as Boston Scientific's Taxus paclitaxel-eluting stent (1"The Gray Sheet" Sept. 17, 2007, p. 4). The 1,548-patient trial met its primary non-inferiority endpoint, showing target vessel failure of 6.8% at nine months, compared to 7.4% for Taxus. But it missed the secondary non-inferiority endpoint of in-segment late loss at eight months (0.36mm versus 0.23mm for Taxus) and nine-month stent thrombosis was higher for Endeavor (0.8% versus 0.1%). Endeavor's worse rates of target lesion revascularization (4.2% versus 2.7%) and target vessel revascularization (5.5% versus 5.0%) were not statistically significant. The Endeavor IV data accompanies an FDA-requested pooled data analysis from all the Endeavor studies in the Circulatory System Devices Panel materials

You may also be interested in...



Medtronic Bullish About Endeavor’s Chances In U.S. Market

Medtronic is confident being the late-comer to the U.S. drug-eluting stent market will not hinder its Endeavor zotarolimus-eluting coronary stent gaining market share

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel